Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
EditorialEditorial

Physical Examination — Still Relevant in Sjögren Syndrome

R. HAL SCOFIELD
The Journal of Rheumatology November 2018, 45 (11) 1495-1496; DOI: https://doi.org/10.3899/jrheum.180834
R. HAL SCOFIELD
Departments of Medicine and Pathology, College of Medicine, University of Oklahoma Health Sciences Center; Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation; Medical and Research Services, Oklahoma City Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for R. HAL SCOFIELD
  • For correspondence: hal-scofield@omrf.ouhsc.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

These days every article requires disclosure of conflicts. And I have one for this editorial — I am a “physical examination” kind of doctor. Surely that is true of almost all rheumatologists because, despite the advances in ultrasound and magnetic resonance imaging, demonstration of the presence of inflammatory arthritis is still largely based on physical examination. And the usefulness of the physical examination is not limited to rheumatology. The techniques developed by René Laennec in part for his newly invented stethoscope (whispered pectoriloquy, egophony, and fremitus) along with the technique developed by Leopold Auenbrugger (percussion)1 are highly sensitive and specific for identifying lung infiltrates and effusions2. A seasoned examiner can diagnose aortic insufficiency more accurately than either M-mode or 2-dimensional echocardiogram3. Thus, the physical examination remains alive and well.

Sjögren syndrome (SS) is a common problem, perhaps second only to rheumatoid arthritis among conditions that cause an inflammatory arthritis4. It can be considered an autoimmune epithelitis5, and predominately affects the exocrine organs. In fact, patients with primary SS can be conveniently divided into those that have disease limited to the exocrine glands such as the salivary and lacrimal and those in whom there are systemic manifestations. Such manifestations include the previously mentioned inflammatory arthritis as well as vasculitis, restrictive and obstructive pulmonary disease, peripheral neuropathy, myositis, interstitial nephritis, glomerulonephritis, central nervous system disease, and lymphoma6. Lymphoma in the setting of SS is commonly mucosa-associated lymphoid tissue (MALT) lymphoma, but can also be other non-Hodgkin lymphomas7,8. While patients with other inflammatory rheumatic diseases are also at increased risk of lymphoma, the risk is definitely greatest among patients with SS9, although lymphoma remains an uncommon complication (Table 1). Nevertheless, predictive and prognostic measures related to lymphoma risk are needed for SS.

View this table:
  • View inline
  • View popup
Table 1.

Lymphoma risk across rheumatic illnesses based on data from the InterLymph consortium from 12 case-control studies of lymphoma in which data on comorbid conditions were collected.

In this issue of The Journal, Zampeli and colleagues provide just such a measure10. And it is a physical finding. Comparing 19 SS patients with MALT lymphoma to 57 SS patients without MALT lymphoma, the authors find that a fissured, atrophic atrophy is more common among those subjects with MALT lymphoma (68%) than those without MALT lymphoma (30%). Only fissured tongue, more severe hyposalivation, and lymphadenopathy were independently associated with MALT lymphoma in a multivariate analysis.

There are limitations to this study, however. Perhaps the most obvious relates to character of the finding and the physical examination required. If the truth be known, most rheumatologists cannot do this examination. The tip of the protruded tongue was grasped and held by the examiner. I think the last time I grasped and held a protruded tongue was as a medical student rotating on otolaryngology at Parkland Hospital in Dallas, Texas. The tongue was divided into posterior, middle and anterior portions. Then, atrophy was graded on a semiquantitative scale (0–2) in each area and for both filiform and fungiform papillae. Dividing the tongue into thirds I can do, but distinguishing, much less identifying, atrophy of the different papillae is, I am equally sure, beyond me (and most other rheumatologists). In fact, the examiners in the paper were oral medicine specialists. This difficulty goes straight to the heart of the evaluation, diagnosis, treatment, and longterm care of these patients. All this takes a team, and it is difficult for many rheumatologists, even those in a comprehensive medical center, to assemble such a team, which requires not only interest in SS but also expertise in pathology, ophthalmology, oral medicine, and rheumatology, at a minimum11. Thus, many physicians will have trouble incorporating this examination of the tongue into the clinical care of SS.

There are other limitations. Because of effects on tongue architecture, patients with diabetes mellitus, iron deficiency, or megaloblastic anemia were excluded. Patients with SS are mostly older adults in whom type 2 diabetes mellitus is a common illness. In addition, any patient with Candida found on periodic acid-Schiff stain of tongue brushings was excluded. Because of xerostomia, oral yeast is a common finding; thus, many patients will be excluded. Of course, this is another part of the examination that general physicians or rheumatologists will not likely be able to replicate in clinical practice. Finally, this study was of MALT lymphoma only. So the results cannot be generalized to all lymphomas to which patients with SS are at risk. And the physical examination finding from this paper cannot be incorporated into other predictive models of lymphoma in SS because these included all lymphoma7,8,10,12–18. The physical findings previously associated with lymphoma risk have been parotid enlargement and splenomegaly18.

Patients with SS are at high risk for lymphoma, and those at high risk need to be monitored carefully. Despite some limitations, the findings of Zampeli, et al10 add another tool to identify those patients at high risk of this, the most serious complication. Incorporation of this examination into the care of SS should be done by oral medicine providers, or rheumatologists if they are able.

Footnotes

  • Supported in part by US National Institutes of Health grants GM104938, AI1082714, and AR053483, as well as a Department of Veterans Affairs Merit Review grant.

  • See Tongue atrophy in SS and MALT, page 1565

REFERENCES

  1. 1.↵
    1. Bynum W
    . The history of medicine: a very short introduction. Oxford: Oxford University Press; 2018:48–52.
  2. 2.↵
    1. Shellenberger RA,
    2. Balakrishnan B,
    3. Avula S,
    4. Ebel A,
    5. Shaik S
    . Diagnostic value of the physical examination in patients with dyspnea. Cleve Clin J Med 2017;84:943–50.
    OpenUrl
  3. 3.↵
    1. Grayburn PA,
    2. Smith MD,
    3. Handshoe R,
    4. Friedman BJ,
    5. DeMaria AN
    . Detection of aortic insufficiency by standard echocardiography, pulsed Doppler echocardiography, and auscultation. A comparison of accuracies. Ann Intern Med 1986;104:599–605.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Helmick CG,
    2. Felson DT,
    3. Lawrence RC,
    4. Gabriel S,
    5. Hirsch R,
    6. Kwoh CK,
    7. et al.
    Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15–25.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Tzioufas AG,
    2. Kapsogeorgou EK,
    3. Moutsopoulos HM
    . Pathogenesis of Sjogren’s syndrome: what we know and what we should learn. J Autoimmun 2012;39:4–8.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Routsias JG,
    2. Goules JD,
    3. Charalampakis G,
    4. Tzima S,
    5. Papageorgiou A,
    6. Voulgarelis M
    . Malignant lymphoma in primary Sjogren’s syndrome: an update on the pathogenesis and treatment. Seminar Arthritis Rheum 2013;43:178–86.
    OpenUrl
  7. 7.↵
    1. Papageorgiou A,
    2. Voulgarelis M,
    3. Tzioufas AG
    . Clinical picture, outcome and predictive factors of lymphoma in Sjogren syndrome. Autoimmun Rev 2015;14:641–9.
    OpenUrl
  8. 8.↵
    1. Chiu YH,
    2. Chung CH,
    3. Lin KT,
    4. Lin CS,
    5. Chen JH,
    6. Chen HC,
    7. et al.
    Predictable biomarkers of developing lymphoma in patients with Sjogren syndrome: a nationwide population-based cohort study. Oncotarget 2017;8:50098–108.
    OpenUrl
  9. 9.↵
    1. Ekström Smedby K,
    2. Vajdic CM,
    3. Falster M,
    4. Engels EA,
    5. Martinez-Maza O,
    6. Turner J,
    7. et al.
    Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008;111:4029–38.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Zampeli E,
    2. Kalogirou EM,
    3. Piperi E,
    4. Mavragani CP,
    5. Moutsopoulos HM
    . Tongue atrophy in Sjögren syndrome patients with mucosa-associated lymphoid tissue lymphoma: autoimmune epithelitis beyond the epithelial cells of salivary glands? J Rheumatol 2018;45:1565–71.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Rasmussen A,
    2. Ice JA,
    3. Li H,
    4. Grundahl K,
    5. Kelly JA,
    6. Radfar L,
    7. et al.
    Comparison of the American-European Consensus Group Sjogren’s syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort. Ann Rheum Dis 2014;73:31–8.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Giannouli S,
    2. Voulgarelis M
    . Predicting progression to lymphoma in Sjogren’s syndrome patients. Expert Rev Clin Immunol 2014;10:501–12.
    OpenUrl
  13. 13.
    1. Nishishinya MB,
    2. Pereda CA,
    3. Munoz-Fernandez S,
    4. Pego-Reigosa JM,
    5. Rua-Figueroa I,
    6. Andreu JL,
    7. et al.
    Identification of lymphoma predictors in patients with primary Sjogren’s syndrome: a systematic literature review and meta-analysis. Rheumatol Int 2015;35:17–26.
    OpenUrlCrossRefPubMed
  14. 14.
    1. Nocturne G,
    2. Virone A,
    3. Ng WF,
    4. Le Guern V,
    5. Hachulla E,
    6. Cornec D,
    7. et al.
    Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjogren’s syndrome. Arthritis Rheumatol 2016;68:977–85.
    OpenUrl
  15. 15.
    1. Quartuccio L,
    2. Baldini C,
    3. Bartoloni E,
    4. Priori R,
    5. Carubbi F,
    6. Corazza L,
    7. et al.
    Anti-SSA/SSB-negative Sjögren’s syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun Rev 2015;14:1019–22.
    OpenUrlCrossRefPubMed
  16. 16.
    1. Quartuccio L,
    2. Isola M,
    3. Baldini C,
    4. Priori R,
    5. Bartoloni Bocci E,
    6. Carubbi F,
    7. et al.
    Biomarkers of lymphoma in Sjögren’s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun 2014;51:75–80.
    OpenUrlCrossRefPubMed
  17. 17.
    1. Tomi AL,
    2. Belkhir R,
    3. Nocturne G,
    4. Desmoulins F,
    5. Berge E,
    6. Pavy S,
    7. et al.
    Brief report: monoclonal gammopathy and risk of lymphoma and multiple myeloma in patients with primary Sjogren’s syndrome. Arthritis Rheumatol 2016;68:1245–50.
    OpenUrl
  18. 18.↵
    1. Baimpa E,
    2. Dahabreh IJ,
    3. Voulgarelis M,
    4. Moutsopoulos HM
    . Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine 2009;88:284–93.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 45, Issue 11
1 Nov 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Physical Examination — Still Relevant in Sjögren Syndrome
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Physical Examination — Still Relevant in Sjögren Syndrome
R. HAL SCOFIELD
The Journal of Rheumatology Nov 2018, 45 (11) 1495-1496; DOI: 10.3899/jrheum.180834

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Physical Examination — Still Relevant in Sjögren Syndrome
R. HAL SCOFIELD
The Journal of Rheumatology Nov 2018, 45 (11) 1495-1496; DOI: 10.3899/jrheum.180834
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • From Prediction Tools to Precision Medicine in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
  • Optimizing Care for Pregnancy in Rheumatic Diseases: Barriers and Potential Solutions
  • High Frequency of Foot Insufficiency Fractures in Patients With Rheumatic Diseases Referred for Magnetic Resonance Imaging: What Is the Clinical Relevance?
Show more Editorial

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire